miRNA Plasmid Composition for CXCR1 Expression Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Bioactive molecules such as CXCR1, when over-expressed or mis-expressed, disrupt homeostasis leading to disease, necessitating therapies to regulate their expression.

Innovation Solution

Compositions comprising recombinant plasmids that encode miRNA sequences targeting CXCR1 mRNA, administered via vectors like AAV, to upregulate miRNA production, thereby downregulating CXCR1 expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CXCR1 is over-expressed to enhance immune response, then immune defense capability is improved, but homeostasis is disrupted leading to disease

Engineering Contradiction:
Improveimmune defense capabilityVSAvoidhomeostasis
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent changes the expression level parameter of CXCR1 by introducing miRNA that specifically targets CXCR1 mRNA for degradation. This reduces CXCR1 protein levels from an over-expressed state to a regulated state, restoring homeostasis while maintaining sufficient immune function through controlled downregulation rather than complete elimination.

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If miRNA is introduced to downregulate CXCR1 expression, then homeostasis is restored, but disease treatment complexity increases

Engineering Contradiction:
ImprovehomeostasisVSAvoidtreatment complexity
Core Design Contradiction:
Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent uses miRNA as an intermediary molecule to mediate the downregulation of CXCR1. Instead of directly targeting the protein or using complex gene editing approaches, the miRNA serves as a natural regulatory intermediary that selectively binds to CXCR1 mRNA, facilitating homeostasis restoration through a biologically compatible mechanism.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs a plasmid copy containing the miRNA sequence that can be introduced into cells. This plasmid copy serves as a template for producing the therapeutic miRNA, allowing for controlled expression of the regulatory molecule without permanently altering the host genome, thus simplifying the treatment approach.

Inventive Principle:
Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Regulates CXCR1 expression, potentially treating or preventing diseases associated with its dysregulation by enhancing endogenous miRNA production to degrade or inactivate CXCR1 mRNA.

Implementation Method 1

The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated

Methodology Applied
Scientific EffectBase pairing:

Implementation Method 2

administered via vectors like AAV, to upregulate miRNA production

Methodology Applied
Scientific EffectViral transduction:

Data Source

PatentUS12480124B1Composition for regulating production of interfering ribonucleic acid
Publication Date: 2025.11.25 WYVERN PHARMACEUTICALS INC

AI summary

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as CXCR1. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.